Refile: BRIEF-Celyad Oncology Had EUR 12.0 Mln In Cash And Cash Equivalents At End-June

Celyad Oncology SA

05/08/2021 07:12

(Refiles to specify the company reported results on Wednesday.)
    Aug 5 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * REPORTED ON WEDNESDAY FIRST HALF 2021 FINANCIAL RESULTS
AND
RECENT BUSINESS HIGHLIGHTS
    * NET LOSS FOR H1 WAS €14.9 MILLION, COMPARED TO NET LOSS
€16.6
MILLION YR AGO
    * AS OF JUNE 30, THE COMPANY HAD CASH AND CASH EQUIVALENTS
OF EUR
12.0 MLN
    * EXISTING CASH AND CASH EQUIVALENTS COMBINED AND ACCESS TO
EQUITY
PURCHASE AGREEMENT WITH LPC SHOULD BE SUFFICIENT TO FUND
OPERATING EXPENSES AND CAPITAL EXPENDITURES TO THE END OF Q3
2022
    * ENROLLMENT CONTINUES AT DOSE LEVEL THREE IN PHASE 1
IMMUNICY-1
TRIAL EVALUATING CYAD-211 IN RELAPSED/REFRACTORY MULTIPLE
MYELOMA (R/R MM); NEXT CLINICAL UPDATE EXPECTED BY YEAR-END 2021
    * WE PLAN ON ANNOUNCING MULTIPLE CLINICAL UPDATES IN THE
NEXT SIX
MONTHS THAT ARE EXPECTED TO HELP FURTHER THE PROGRESS OF OUR
LEAD PROGRAMS AND PROPRIETARY SHRNA PLATFORM FOR THE DEVELOPMENT
OF NEXT-GENERATION ALLOGENEIC CAR TS - CEO
    * R&D EXPENSES WERE €10.0 MILLION FOR THE FIRST HALF OF
2021,
COMPARED TO €11.1 MILLION FOR THE FIRST HALF OF 202
    * NET CASH USED IN OPERATIONS, WHICH EXCLUDES NON-CASH
EXPENSES,
WAS €12.2 MILLION FOR THE FIRST HALF OF 2021, COMPARED TO €14.6
MILLION FOR THE FIRST HALF OF 2020

Source text for Eikon:  ID:nGNXmvmBd 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))